Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS

Andrew C. Elden, Hyung Jun Kim, Michael P. Hart, Alice S. Chen-Plotkin, Brian S. Johnson, Xiaodong Fang, Maria Armakola, Felix Geser, Robert Greene, Min Min Lu, Arun Padmanabhan, Dana Clay-Falcone, Leo McCluskey, Lauren Elman, Denise Juhr, Peter J. Gruber, Udo Rüb, Georg Auburger, John Q. Trojanowski, Virginia M.Y. LeeVivianna M. Van Deerlin, Nancy M. Bonini, Aaron D. Gitler

Research output: Contribution to journalArticlepeer-review

820 Scopus citations


The causes of amyotrophic lateral sclerosis (ALS), a devastating human neurodegenerative disease, are poorly understood, although the protein TDP-43 has been suggested to have a critical role in disease pathogenesis. Here we show that ataxin 2 (ATXN2), a polyglutamine (polyQ) protein mutated in spinocerebellar ataxia type 2, is a potent modifier of TDP-43 toxicity in animal and cellular models. ATXN2 and TDP-43 associate in a complex that depends on RNA. In spinal cord neurons of ALS patients, ATXN2 is abnormally localized; likewise, TDP-43 shows mislocalization in spinocerebellar ataxia type 2. To assess the involvement of ATXN2 in ALS, we analysed the length of the polyQ repeat in the ATXN2 gene in 915 ALS patients. We found that intermediate-length polyQ expansions (27-33 glutamines) in ATXN2 were significantly associated with ALS. These data establish ATXN2 as a relatively common ALS susceptibility gene. Furthermore, these findings indicate that the TDP-43-ATXN2 interaction may be a promising target for therapeutic intervention in ALS and other TDP-43 proteinopathies.

Original languageEnglish (US)
Pages (from-to)1069-1075
Number of pages7
Issue number7310
StatePublished - Aug 26 2010
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS'. Together they form a unique fingerprint.

Cite this